Back to top
more

Leap Therapeutics (LPTX)

(Delayed Data from NSDQ)

$3.07 USD

3.07
130,419

-0.18 (-5.54%)

Updated Apr 29, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA

by Zacks Equity Research

The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.

Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why

by Zacks Equity Research

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod

by Zacks Equity Research

The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development

by Zacks Equity Research

Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.

    Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study

    by Zacks Equity Research

    Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.

    Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED

    by Zacks Equity Research

    Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.

    Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease

    by Zacks Equity Research

    Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.

    Praxis (PRAX) Tanks on Negative Data From Depression Study

    by Zacks Equity Research

    Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.

    Global Blood's (GBT) Candidates for SCD Get Two FDA Tags

    by Zacks Equity Research

    The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.

    GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix

    by Zacks Equity Research

    The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.

    Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study

    by Zacks Equity Research

    Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.

    Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails

    by Zacks Equity Research

    Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.

    Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug

    by Zacks Equity Research

    Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.

    Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy

    by Zacks Equity Research

    Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

    Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug

    by Zacks Equity Research

    The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.

    GSK to Boost Vaccine Portfolio With Affinivax Acquisition

    by Zacks Equity Research

    GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.

    Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe

    by Zacks Equity Research

    Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive. However, sole dependence on Oxbryta for growth is a concern.

    INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

    by Zacks Equity Research

    The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

    SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

    by Zacks Equity Research

    SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

    Seagen (SGEN) Posts Positive Data from New Study on Tukysa

    by Zacks Equity Research

    Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.

    AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

    by Zacks Equity Research

    AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.

    Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata

    by Zacks Equity Research

    The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.

    Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Leap Therapeutics, Inc. (LPTX) Q3 Earnings Expected to Decline

    by Zacks Equity Research

    Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.